Non-coding NAT2 variants also have been associated with increased cardiovascular medication usage, which indirectly supports that dyslipidemia conferred by risk alleles of NAT2 variants can result in clinically pathological conditions. This evidence concerns the gene NAT2 and metabolic syndrome.